NCT05743426Recruiting
Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies
Source: ClinicalTrials.gov · Last updated 30 Mar 2026
Brief summary (registry, in English)
This prospective, single-institution, observational study explores disease outcomes and toxicities in subjects with gastrointestinal malignancies and sarcoma (bone and soft tissue) who are being treated with standard-of-care therapies including radiotherapy. Recent advances in treatment approaches affected disease outcomes and toxicities. Prospective monitoring of disease outcomes and toxicities using standardized assessments will provide information about recent changes in the standard of care and further refine treatment approaches and prospective clinical trial design.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 180 (estimated)
- First submitted
- 14 Feb 2023
- Start date
- 17 Mar 2023
- Primary completion date
- 1 Jan 2036
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Diseases
- Sarcoma
- NCT number
- NCT05743426
What you commit to
- Study type: Observational
- Planned participants: 180
- From 17 Mar 2023 to the primary completion date, 1 Jan 2036
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- All subjects meeting any exclusion criteria at baseline will be excluded from study participation.
- Inability or unwillingness to provide informed consent
- Patients who state they do not expect to be available or willing to follow up at expected intervals post-treatment
Who the study is looking for
- In order to participate in this study a subject must meet all of the eligibility criteria outlined below.
- Subject is willing and able to provide written informed consent to participate in the study and HIPAA authorization for the release of personal health information. Subjects are willing and able to comply with study procedures based on the judgment of the investigator or protocol designer.
- Age ≥ 18 years at the time of consent.
- Histological, cytological, or radiographic evidence/confirmation of a gastrointestinal malignancy or sarcoma.
- Females with childbearing potential and male subjects with fathering potential are allowed to participate in this study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of North Carolina at Chapel Hill, Department of Radiation Oncology Coordinator of this site? Confirm its status | Chapel Hill | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.